MarketCap
Facebook
X
TelegramAnnual report 2024
added 01-03-2026
BioLineRx Ltd. Cash and Cash Equivalents 2011-2026 | BLRX
Annual Cash and Cash Equivalents BioLineRx Ltd.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 10.4 M | 4.26 M | 10.6 M | 13 M | 16.8 M | 5.3 M | 3.4 M | 5.11 M | 2.47 M | 5.54 M | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 16.8 M | 2.47 M | 7.69 M |
Quarterly Cash and Cash Equivalents BioLineRx Ltd.
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 13 M | - | 17.5 M | - | 16.8 M | - | 5.52 M | - | 5.3 M | - | 4.97 M | - | 3.4 M | - | 5.79 M | - | 5.11 M | - | 6.95 M | - | 2.47 M | - | - | - | 5.54 M | - | - | - | 5.79 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 17.5 M | 2.47 M | 7.55 M |
Cash and Cash Equivalents of other stocks in the Biotechnology industry
| Issuer | Cash and Cash Equivalents | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
158 M | - | 2.43 % | $ 254 M |  Germany |
 |
AgeX Therapeutics
AGE
|
345 K | - | -10.17 % | $ 12.2 K |  USA |
 |
Autolus Therapeutics plc
AUTL
|
240 M | $ 1.37 | -8.67 % | $ 350 M |  Britain |
 |
Aeglea BioTherapeutics
AGLE
|
89.4 M | - | - | $ 1.01 B | USA |
 |
Adagene
ADAG
|
75.2 M | $ 1.65 | 6.11 % | $ 92.9 M |  China |
 |
Alterity Therapeutics Limited
ATHE
|
34.8 M | $ 3.43 | -2.69 % | $ 8.25 B |  Australia |
 |
Biogen
BIIB
|
2.38 B | $ 177.93 | -4.15 % | $ 25.9 B | USA |
 |
Arrowhead Pharmaceuticals
ARWR
|
227 M | $ 65.89 | -0.06 % | $ 8.81 B | USA |
 |
Biophytis SA
BPTS
|
5.57 M | - | -13.47 % | $ 169 M |  France |
 |
Akero Therapeutics
AKRO
|
340 M | - | - | $ 3.67 B | USA |
 |
AVROBIO
AVRO
|
98 M | - | 1083.1 % | $ 745 M | USA |
 |
Midatech Pharma plc
MTP
|
1.67 M | - | -18.52 % | $ 27.3 M | Britain |
 |
AstraZeneca PLC
AZN
|
5.49 B | $ 94.4 | 0.82 % | $ 96.9 B | Britain |
 |
BeiGene, Ltd.
BGNE
|
2.63 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Bellicum Pharmaceuticals
BLCM
|
21.8 M | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
86.5 M | - | -7.31 % | $ 87 M | USA |
 |
Ascendis Pharma A/S
ASND
|
560 M | $ 214.55 | 2.77 % | $ 5 B |  Danmark |
 |
Codiak BioSciences
CDAK
|
76.9 M | - | -55.98 % | $ 2.15 M | USA |
 |
ARCA biopharma
ABIO
|
61.6 M | - | 1052.0 % | $ 415 M | USA |
 |
Bristol-Myers Squibb Company
BMY
|
10.3 B | $ 55.84 | 0.13 % | $ 113 B | USA |
 |
Cerevel Therapeutics Holdings
CERE
|
416 M | - | - | $ 7.29 B | USA |
 |
Acasti Pharma
ACST
|
22.1 M | - | 4.01 % | $ 150 M |  Canada |
 |
Caladrius Biosciences
CLBS
|
16.2 M | - | -16.75 % | $ 25.8 M | USA |
 |
Clearside Biomedical
CLSD
|
28.9 M | - | - | $ 25.3 M | USA |
 |
Chimerix
CMRX
|
27.7 M | - | - | $ 756 M | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
144 M | - | -15.15 % | $ 60.3 M | Britain |
 |
BioNTech SE
BNTX
|
9.76 B | $ 106.88 | 4.6 % | $ 27.2 B | Germany |
 |
Can-Fite BioPharma Ltd.
CANF
|
8.27 M | $ 4.18 | -1.65 % | $ 9.1 B |  Israel |
 |
AIkido Pharma
AIKI
|
4.08 M | - | 1.93 % | $ 17.4 M | USA |
 |
Catalyst Biosciences
CBIO
|
33.5 M | $ 11.09 | 1.0 % | $ 730 M | USA |
 |
Albireo Pharma
ALBO
|
248 M | - | -0.23 % | $ 916 M | USA |
 |
CureVac N.V.
CVAC
|
811 M | - | - | $ 867 M | Germany |
 |
Acer Therapeutics
ACER
|
2.33 M | - | 2.71 % | $ 14 M | USA |
 |
Alpine Immune Sciences
ALPN
|
13.4 M | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
118 M | - | 4.14 % | $ 49.1 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
2.41 M | - | - | $ 7.46 M | Israel |
 |
Coherus BioSciences
CHRS
|
103 M | $ 1.69 | 2.12 % | $ 159 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
4.09 M | - | -11.43 % | $ 502 K | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
152 M | $ 28.99 | -1.39 % | $ 1.4 B | USA |
 |
Celldex Therapeutics
CLDX
|
28.4 M | $ 25.71 | 0.16 % | $ 1.66 M | USA |
 |
CTI BioPharma Corp.
CTIC
|
30.4 M | - | - | $ 1.2 B | USA |
 |
Cellectis S.A.
CLLS
|
143 M | $ 4.24 | -0.47 % | $ 116 M | France |
 |
Acorda Therapeutics
ACOR
|
30 M | - | -24.86 % | $ 820 K | USA |
|
Applied Molecular Transport
AMTI
|
61.1 M | - | - | $ 10.1 M | USA |
 |
Brickell Biotech
BBI
|
10.9 M | - | -5.38 % | $ 6.06 M | USA |
 |
Burford Capital Limited
BUR
|
322 M | $ 9.57 | -0.78 % | $ 1.55 B | Britain |